Moleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by Maxim Group

Maxim Group upgraded shares of Moleculin Biotech (NASDAQ:MBRX) from a hold rating to a buy rating in a research report released on Tuesday, MarketBeat.com reports. The firm currently has $4.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the company. StockNews.com started coverage on Moleculin Biotech in a research report on Thursday, March 13th. They set a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Moleculin Biotech in a report on Monday.

Moleculin Biotech Stock Down 1.9 %

Shares of NASDAQ:MBRX opened at $1.05 on Tuesday. The business has a 50-day moving average of $1.30 and a two-hundred day moving average of $1.99. Moleculin Biotech has a fifty-two week low of $0.40 and a fifty-two week high of $6.23.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.